Description: A look at the near future and far future of various elements of Actuarial Models as defined through ASOP 51. What is driving the complexity for inputs, calculations, and outputs. Howe will actuaries handle these challenge?

Description: "Minimum Social Security Benefit (s) and the Alone Stage of Retirement in the U.S.? – Lori J. Curtis, PhD., Douglas Andrews, FSA, FCIA, Ph.D., University of Waterloo The Importance of Cognitive Health – Gordon Woo,Ph.D., RMS LifeRisks"

Description: "How long is long in longevity? – Jesús-Adrian Álvarez, Ph.D. - Danish Labour Market Supplementary Pension Fund (ATP), The Rate of Aging in humans is constant. New evidence – Marcus Ebeling, PhD., Research Group Mathematical and Actuarial Demography, Max Planck Institute for Demographic Research, Rostock, Germany, Department of Sociology and Demography, University of Rostock, Rostock, Germany; Roland Rau, Ph.D., Professor, Research Group Mathematical and Actuarial Demography, Max Planck Institute for Demographic Research, Rostock, Germany, C6 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Håkan Malmström, Ph.D., C6 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Anders Ahlbom, Ph.D., Professor Emeritus, Karen Modig, Ph.D., Associate Professor, C6 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden Human Lifetimes: Finite But Not Necessarily Bounded – Fei Huang, PhD., School of Risk & Actuarial Studies, UNSW Sydney; Ross Maller, Ph.D., Emeritus Professor, Xu Ning, Ph.D., Research School of Finance, Actuarial Studies & Statistics, Australian National University, Brandon Milholland, Ph.D., IQVIA Plymouth Meeting, PA."

Description: Most of our standard risk management processes are designed to work well within a shifting environment that stays fundamentally the same over time. We are likely to experience something drastically different starting soon - a major regime change. This webinar addresses how we might react to such turbulent times both to survive current issues and prepare to thrive in a new future. Participants will learn how scenario planning can be used to help envision a way forward. A case study will look at the ways that this regime change might affect our cities, how that could affect insurers and how both cities and insurers can approach the transition period as well as plotting a course for the future regime.

Description: Attend this webcast to learn more on how to navigate managing ESG principles in the new normal of a post-COVID world. Enhance your ESG insights in a post-pandemic landscape.

Description: The traditional defined-benefit (DB) plan is a type of plan structured to provide the greatest degree of retirement income security, designed to pay out a guaranteed retirement income for the life of the retiree (and, when applicable, a beneficiary). However, over the last several decades, the number of private-sector employees covered under these traditional plans has decreased dramatically and been replaced by defined contribution (DC) plans. In contrast, public-sector retirement plans, which are exempt from ERISA, have seen a much smaller decline in DB plans. There are many differences in the private and public sector that likely contributed to this phenomenon, but ERISA and the many amendments to it has been a major factor.

Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: Forward looking insurers are reimagining their businesses with key strategic aims around how they engage with their customers and how they make and implement decisions. Industry experts will present a maturity framework for assessing your progress with specific case studies for how to advance in the areas of Management Information, New Business, and Inforce Management.

Description: "Driving Longevity Through Educational Attainment – Robert L. Brown – Ph. D. Higher Age U.S. Mortality By Education and Cause of Death Trends, Inequality and Controllable Risk Factors – Andrew J. G. Cairns – MPA Ph.D., Maxwell Institute for Mathematical Sciences, and Department of Actuarial Mathematics and Statistics, Heriot-Watt University, Edinburgh, Scotland, UK, Cristian Redondo Lour´es, Ph.D., Actuarial Solutions,"